Ovarian Cancer Recurrent Clinical Trials

28 clinical trials for Ovarian Cancer Recurrent across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) — RECRUITING · PHASE1
• A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse 022/ENGOT ov84/GOG-3103) — RECRUITING · PHASE3
• SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy — RECRUITING · PHASE2
• A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer — RECRUITING · PHASE1
• A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer — RECRUITING · PHASE1
• A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB — RECRUITING
• IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer — RECRUITING · PHASE2
• Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer — RECRUITING · PHASE2
• Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer. — RECRUITING · PHASE1
• Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) — RECRUITING · PHASE2
• Longitudinal Plasma Proteomic Remodeling in Ovarian Cancer — COMPLETED · NA
• A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. — NOT_YET_RECRUITING · PHASE1
• Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer — WITHDRAWN · PHASE1
• Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse) — NOT_YET_RECRUITING · PHASE2
• Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer — COMPLETED · PHASE2
• A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) — TERMINATED · PHASE1
• The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients — NOT_YET_RECRUITING · NA
• Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors — OTHER · PHASE2
• Microtransplantation for Ovarian Cancer — OTHER · PHASE1
• Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer — OTHER · NA
• DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer — COMPLETED · PHASE2
• Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer — OTHER · PHASE1
• The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer — TERMINATED · PHASE1
• A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer. — COMPLETED · PHASE1
• A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse — COMPLETED · PHASE1
• Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel — COMPLETED · PHASE2
• EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer — COMPLETED · PHASE2

Refine this search